Clinical trial of SR141716, Rimonabant, to reduce volunt

SR141716、利莫那班的临床试验，以减少自愿

• 批准号: 6983095
• 负责人: David T George
• 金额: --
• 依托单位: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6983095
• 关键词: alcoholic beverage consumption; alcoholism /alcohol abuse; alcoholism /alcohol abuse chemotherapy; alcoholism antagonist; breath tests; cannabinoid receptor; clinical trials; drug screening /evaluation; human subject; human therapy evaluation; inhibitor /antagonist; patient oriented research

The objective of this research is to determine if the investigational drug SR141716 (Rimonabant) decreases voluntary ethanol consumption in humans. The study population will be comprised of non-treatment seeking volunteers, who normally consume between 20 and 40 alcohol drinks per day. Study volunteers will receive either placebo or SR141716 three weeks prior to participating in an alcohol self-administration experiment conducted in a controlled environment. Following baseline psychological and endocrine measures, the volunteer's breath alcohol level will be raised to 0.03 g/dl. Over the next two-hour period, the volunteer will have the opportunity to consume up to eight drinks or receive a monetary reward for each drink not consumed. Rimonabant was made available to NIAAA in August 2004. To date three participants have completed the protocol. Six additional participants are scheduled for participation. Study remains blinded.

本研究的目的是确定研究药物SR 141716（利莫那班）是否减少人类的自愿乙醇消耗。研究人群将由非寻求治疗的志愿者组成，他们通常每天饮用20至40杯酒精饮料。研究志愿者将在参与在受控环境中进行的酒精自我给药实验前3周接受安慰剂或SR 141716。在基线心理和内分泌测量之后，志愿者的呼气酒精水平将升高至0.03 g/dl。在接下来的两个小时内，志愿者将有机会喝下最多八杯饮料，或者每喝一杯就获得一笔奖金。 利莫那班于2004年8月提供给NIAAA。迄今为止，已有三名参与者完成了方案。另有6名学员计划参加。研究保持盲态。